Piper Jaffray analyst Charles Duncan reiterated an Overweight rating and bumped his price target on Cara Therapeutics (NASDAQ: CARA) to ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst PT Change

Cara Therapeutics (CARA) Fair Value Target Lifted to $27 at Janney CapitalJuly 23, 2015 10:45 AM Cara Therapeutics (CARA) PT Raised to $27 at Needham & CompanyJuly 23, 2015 9:50 AM Pre-Open Stock Movers 07/23: (CARA) (SNDK) (CRUS) Higher; (CVA) (URI) (SCSS) Lower (more...)July 23, 2015 9:30 AM Cara Therapeutics (CARA) Announces Statistically Significant Results From Phase 2 Trial in Uremic PruritusJuly 23, 2015 8:45 AM Cara Therapeutics Announces Positive Results From Phase 2 Trial in Uremic PruritusJuly 23, 2015 7:01 AM